UNSPSC 51172182: Tiropramide hydrochloride

This classification denotes a parasympatholytic and tyrosine analog C28H41N3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9523013Y6R, chemically known as benzenepropanamide, alpha-(benzoylamino)-4-(2-(diethylamino)ethoxy)- n,n-dipropyl-, hydrochloride, (+/-)-, but more generally known as tiropramide hydrochloride, which bears US NIH Compound Identifier 134448. European Medicines Agency schedules Tiropramide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15577MIG.

Most nations, for tariff and trade purposes, schedule tiropramide hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, TIROPRAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCN(CCC)C(=O)C(CC1CCC(CC1)OCCN(CC)CC)NC(=O)C2CCCCC2.CL.

UNSPSC 51172182 Tiropramide hydrochloride is a Commodity code nominally designating a single pharmaceutical agent, but recent state and local solicitations posted under this code reflect substantial scope mismatch with the specific drug name. The three opportunities on file—an offender specimen collection and drug testing services RFP from Collin County, a therapeutic pharmacy initiative exploratory RFI from Texas HHS, and a multistate generic pharmaceuticals and OTC products cooperative purchasing agreement from MMCAP—concern broad pharmacy benefit management, laboratory testing, and pharmaceutical supply logistics rather than tiropramide hydrochloride procurement specifically. The code appears to capture diverse pharmaceutical and clinical-chemistry contracting activity across Texas state agencies and multistate purchasing cooperatives, spanning specimen collection and testing services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements.

Collin County Community Supervision and Corrections Department posted the most concrete recent opportunity: RFP 2026-327 for offender specimen collection and drug testing services, with responses due July 23, 2026, seeking staffing at two Texas collection sites (Plano and McKinney), interactive voice response systems for randomized testing notifications, immunoassay and mass-spectrometry screening and confirmation, and alternative testing methodologies (oral fluid and hair testing). The contract is estimated at $600,000 over two years with three optional one-year renewals through September 2029, with award anticipated August 10, 2026. Texas HHS issued a preliminary RFI (HHS0017013) in late March 2026 to gather vendor capabilities around direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by Minnesota's Department of Administration and covering Oregon and other participating jurisdictions, posted an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness.